Josep M. del Campo

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

Andreas du Bois, Anne Floquet, Jae‐Weon Kim et al. · Journal of Clinical Oncology · 2014 · 318 citations · Full text

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Josep M. del Campo, Ursula A. Matulonis, Susanne Malander et al. · Journal of Clinical Oncology · 2019 · 184 citations · Full text

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee et al. · Journal of Clinical Oncology · 2020 · 144 citations · Full text

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

Josep M. del Campo, Michael J. Birrer, Craig B. Davis et al. · Gynecologic Oncology · 2016 · 130 citations

Medicine, Gynecology, Recurrent Endometrial Cancer +6

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Amit M. Oza, Ursula A. Matulonis, Susanne Malander et al. · The Lancet Oncology · 2018 · 123 citations

Medicine, Cancer Management, Gynecology +7